title: Early clinical complications after ABO-incompatible live-donor kidney transplantation: a national study of Medicare-insured recipients.
abstract: BACKGROUND
  Descriptions of the sequelae of ABO-incompatible (ABOi) kidney transplantation are limited to single-center reports, which may lack power to detect important effects.
  
  
  METHODS
  We examined U.S. Renal Data System registry data to study associations of ABOi live-donor kidney transplantation with clinical complications in a national cohort. Among 14,041 Medicare-insured transplants in 2000 to 2007, 119 non-donor-A2 ABOi transplants were identified. A2-incompatible (n=35) transplants were categorized separately. Infection and hemorrhage events were identified by diagnosis codes on billing claims. Associations of ABO incompatibility with complications were assessed by multivariate Cox regression.
  
  
  RESULTS
  Recipients of ABOi transplants experienced significantly (P<0.05) higher incidence of wound infections (12.7% vs. 7.3%), pneumonia (7.6% vs. 3.8%), and urinary tract infections (UTIs) or pyelonephritis (24.5% vs. 15.3%) in the first 90 days compared with ABO-compatible recipients. In adjusted models, ABO incompatibility was associated with twice the risk of pneumonia (adjusted hazard ratio [aHR], 2.22; 95% confidence interval [CI], 1.14-4.33) and 56% higher risk of UTIs or pyelonephritis (aHR, 1.56; 95% CI, 1.05-2.30) in the first 90 posttransplantation days, and 3.5 times the relative risk of wound infections in days 91 to 365 (aHR, 3.55; 95% CI, 1.92-6.57). ABOi recipients, 19% of whom underwent pre- or peritransplant splenectomy, experienced twice the adjusted risk of early hemorrhage (aHR, 1.96; 95% CI, 1.19-3.24). A2-incompatible transplantation was associated only with early risk of UTIs or pyelonephritis.
  
  
  CONCLUSIONS
  ABOi transplantation offers patients with potential live donors an additional transplant option but with higher risks of infectious and hemorrhagic complications. Awareness of these complications may help improve protocols for the management of ABOi transplantation.
authors: 1 Center for Outcomes Research, Saint Louis University School of Medicine, St. Louis, MO. 2 Division of Abdominal Transplantation, Department of Surgery, Saint Louis University School of Medicine, St. Louis, MO. 3 Division of Abdominal Transplantation, Department of Surgery, Dartmouth Hitchcock Medical Center, Hanover, NH. 4 Transplant Nephrology, Washington University School of Medicine, St. Louis, MO. 5 Division of Abdominal Transplantation, Department of Surgery, Johns Hopkins University, Baltimore, MD. 6 Address correspondence to: Krista L. Lentine, M.D., Ph.D., Saint Louis University Center for Outcomes Research, Salus Center 4th Floor, 3545 Lafayette Ave, St. Louis, MO 63104.
authors: Krista L
authors: KL
authors: Lentine
authors: David
authors: D
authors: Axelrod
authors: Christina
authors: C
authors: Klein
authors: Christopher
authors: C
authors: Simpkins
authors: Huiling
authors: H
authors: Xiao
authors: Mark A
authors: MA
authors: Schnitzler
authors: Janet E
authors: JE
authors: Tuttle-Newhall
authors: Vikas R
authors: VR
authors: Dharnidharka
authors: Daniel C
authors: DC
authors: Brennan
authors: Dorry L
authors: DL
authors: Segev
mesh_terms: D000017:ABO Blood-Group System / Q000276:immunology*; D000328:Adult; D001787:Blood Group Incompatibility / Q000276:immunology*; D005260:Female; D006648:Histocompatibility; D006801:Humans; D053208:Kaplan-Meier Estimate; D016030:Kidney Transplantation / Q000009:adverse effects*; D019520:Living Donors; D008297:Male; D006278:Medicare; D008875:Middle Aged; D015999:Multivariate Analysis; D019106:Postoperative Hemorrhage / Q000209:etiology*; D016016:Proportional Hazards Models; D011704:Pyelonephritis / Q000209:etiology*; D012042:Registries; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States; D014552:Urinary Tract Infections / Q000209:etiology*
chemical_list: D000017:ABO Blood-Group System